DB:FYB

Stock Analysis Report

Executive Summary

Formycon AG engages in the development and marketing of biosimilar products.


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Formycon's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FYB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-6.2%

FYB

-8.1%

DE Biotechs

-6.8%

DE Market


1 Year Return

-12.2%

FYB

2.8%

DE Biotechs

6.5%

DE Market

Return vs Industry: FYB underperformed the German Biotechs industry which returned 2.8% over the past year.

Return vs Market: FYB underperformed the German Market which returned 6.5% over the past year.


Shareholder returns

FYBIndustryMarket
7 Day-6.2%-8.1%-6.8%
30 Day-17.9%-9.4%-3.7%
90 Day-19.0%-4.5%-3.6%
1 Year-12.2%-12.2%3.0%2.8%9.8%6.5%
3 Year10.4%10.4%31.3%29.9%6.8%-2.6%
5 Year48.7%48.7%6.9%4.6%12.5%-2.9%

Price Volatility Vs. Market

How volatile is Formycon's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Formycon undervalued compared to its fair value and its price relative to the market?

5.22x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate FYB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate FYB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: FYB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: FYB is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate FYB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FYB is overvalued based on its PB Ratio (5.2x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Formycon forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-96.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FYB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: FYB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: FYB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: FYB's revenue is expected to decline over the next 3 years (-2.5% per year).

High Growth Revenue: FYB's revenue is forecast to decline over the next 3 years (-2.5% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if FYB's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Formycon performed over the past 5 years?

35.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FYB is currently unprofitable.

Growing Profit Margin: FYB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: FYB is unprofitable, but has reduced losses over the past 5 years at a rate of 35% per year.

Accelerating Growth: Unable to compare FYB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FYB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: FYB has a negative Return on Equity (-2.38%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Formycon's financial position?


Financial Position Analysis

Short Term Liabilities: FYB's short term assets (€28.3M) exceed its short term liabilities (€3.5M).

Long Term Liabilities: FYB's short term assets (€28.3M) exceed its long term liabilities (€702.1K).


Debt to Equity History and Analysis

Debt Level: FYB is debt free.

Reducing Debt: FYB had no debt 5 years ago.


Balance Sheet

Inventory Level: FYB has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if FYB's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if FYB has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if FYB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Formycon's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate FYB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate FYB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FYB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FYB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FYB's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average board tenure


CEO

Carsten Brockmeyer 0

6.8yrs

Tenure

0

Dr. Carsten Brockmeyer, PhD, has been Chief Executive Officer and Member of Executive Board at Formycon AG since April 16, 2013 and served as its Chairman of Executive Board. Dr. Brockmeyer has more than 2 ...


Board Members

NamePositionTenureCompensationOwnership
Bernhard Hampl
Member of Advisory Board5.9yrsno datano data
Gerhard Schaefer
Member of Advisory Board6.3yrsno datano data
Hermann Vogt
Deputy Chairman of Supervisory Board0yrsno datano data
Olaf Stiller
Chairman of Supervisory Board0yrsno datano data
Peter Wendeln
Member of Supervisory Board0yrsno datano data
Johannes Buchner
Member of Advisory Board4yrsno datano data
Thomas Siklosi
Member of Advisory Board1.5yrsno datano data

5.0yrs

Average Tenure

Experienced Board: FYB's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7%.


Top Shareholders

Company Information

Formycon AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Formycon AG
  • Ticker: FYB
  • Exchange: DB
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €260.000m
  • Shares outstanding: 10.00m
  • Website: https://www.formycon.com

Number of Employees


Location

  • Formycon AG
  • Fraunhoferstrasse 15
  • Martinsried
  • Planegg
  • Bavaria
  • 82152
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FYBDB (Deutsche Boerse AG)YesBearer SharesDEEURDec 2010
FYBXTRA (XETRA Trading Platform)YesBearer SharesDEEURDec 2010
0W4NLSE (London Stock Exchange)YesBearer SharesGBEURDec 2010
FYBDBATS-CHIXE (BATS 'Chi-X Europe')YesBearer SharesGBEURDec 2010

Biography

Formycon AG engages in the development and marketing of biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis 1, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases that is in the Phase III clinical trials; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease, which is in the preclinical stage; and FYB203, a biosimilar candidate for Eylea 3, like Lucentis, Eylea, used to treat neovascular age-related macular degeneration and other eye diseases that is in the preclinical study. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is based in Planegg, Germany. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/26 22:41
End of Day Share Price2020/02/26 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.